All In MedTech

FDA Clearance Tracker · P970004-S153

INTERSTIM THERAPY FOR URINARY CONTROL

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 15, 2014 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 15, 2014

Approved

Time to decision

404 days

Received Mar 7, 2013. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P970004-S153
Device name
INTERSTIM THERAPY FOR URINARY CONTROL
Applicant location
Minneapolis, MN
Received
Mar 7, 2013
Decided
Apr 15, 2014
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P970004

Device type

Device class
Class III
Regulation
21 CFR 876.5270

Every decision under product code EZW

FDA's approval statement

As written in FDA's record.

APPROVAL FOR LABELING UPDATES TO INCORPORATE THE LONG-TERM DATA FROM THE FECAL INCONTINENCE POST-APPROVAL STUDY INTO THE INTERSTIM THERAPY LABELING.

Source documents

Other decisions for Medtronic Neuromodulation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.